472 related articles for article (PubMed ID: 2454260)
21. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes.
Han X; Itoh K; Balch CM; Pellis NR
Lymphokine Res; 1988; 7(3):227-35. PubMed ID: 3263554
[TBL] [Abstract][Full Text] [Related]
22. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
23. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
Burns GF; Triglia T; Werkmeister JA
J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
[TBL] [Abstract][Full Text] [Related]
24. TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells.
Jin B; Scott JL; Vadas MA; Burns GF
Immunology; 1989 Apr; 66(4):570-6. PubMed ID: 2541074
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
26. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
Brooks CG; Holscher M; Urdal D
J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
[TBL] [Abstract][Full Text] [Related]
27. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.
Okada M; Kitahara M; Kishimoto S; Matsuda T; Hirano T; Kishimoto T
J Immunol; 1988 Sep; 141(5):1543-9. PubMed ID: 3261754
[TBL] [Abstract][Full Text] [Related]
28. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
30. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
31. Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro.
Gately MK; Wilson DE; Wong HL
J Immunol; 1986 Feb; 136(4):1274-82. PubMed ID: 2418110
[TBL] [Abstract][Full Text] [Related]
32. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
33. IL-10: a novel cytotoxic T cell differentiation factor.
Chen WF; Zlotnik A
J Immunol; 1991 Jul; 147(2):528-34. PubMed ID: 1906502
[TBL] [Abstract][Full Text] [Related]
34. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone.
Hayakawa K; Salmeron MA; Kornbluth J; Bucana C; Itoh K
J Immunol; 1991 Apr; 146(7):2453-60. PubMed ID: 1900882
[TBL] [Abstract][Full Text] [Related]
35. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes.
Mehrotra PT; Wu D; Crim JA; Mostowski HS; Siegel JP
J Immunol; 1993 Sep; 151(5):2444-52. PubMed ID: 8103066
[TBL] [Abstract][Full Text] [Related]
36. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
Drobyski WR; LeFever AV; Truitt RL
Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
[TBL] [Abstract][Full Text] [Related]
37. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.
Patel SS; Thiele DL; Lipsky PE
J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232
[TBL] [Abstract][Full Text] [Related]
38. The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation.
Nagler A; Lanier LL; Phillips JH
J Immunol; 1988 Oct; 141(7):2349-51. PubMed ID: 3262658
[TBL] [Abstract][Full Text] [Related]
39. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
40. Cellular and molecular mechanisms of the IL-12-induced increase in allospecific murine cytolytic T cell activity. Implications for the age-related decline in CTL.
Bloom ET; Horvath JA
J Immunol; 1994 May; 152(9):4242-54. PubMed ID: 7908914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
